EDEN

THE NATURAL SOLUTION

Eden Research plc (AIM: EDEN)

Company Summary

WALBROOK INVESTOR RELATIONS

September 2026

Investment Profile

1. Differentiated formulation technology – Proprietary Sustaine® platform addresses industry trends relating to sustainable crop protection.
2. Asset-light partner model - Established commercial partnerships provide scalable access to global markets.
3. Multiple growth levers - New registrations, products, and geographies provide an expanding addressable market and support for future growth.
4. Attractive market tailwinds - Regulatory change, consumer sentiment and pest resistance are accelerating demand for sustainable crop-protection solutions.

Share Information

Ticker	AIM: EDEN
Share Price (GBX)	2.10
Shares in issue (m)	803
Market Cap (£m)	17.27
12m Hi/Low (GBX)	5.00/1.96

(Source: The London Stock Exchange, September 2026)

12-Month Share Price

(Source: The London Stock Exchange, September 2026)

Major Shareholders (as at 19 June 2026)

Name	%
Gresham House Asset Mgt	22.14
Octopus Investments	11.40
Canaccord Genuity Wealth Mgt	8.44
Hargreaves Lansdown	7.74
Unicorn Asset Mgt	7.54
Interactive Investor	5.82
Sipcam Oxon S.p.A	4.89
Atul Unadkat	4.11
Rathbones	3.23
Maven Capital Partners	3.09

(Source: Company website)

Company Overview

Eden Research is an intellectual property, product development, registration and commercialisation business harnessing natural plant chemistry through its Sustaine® microencapsulation platform with a commercial focus on the global crop protection industry.

Eden has built one of the largest regulatory footprints in biological crop protection, with approvals across 33 countries, a patent portfolio exceeding 130 granted or pending patents and multiple commercial products. The Company derives 100% of revenues from sustainable products and was included in the London Stock Exchanges 2026 Green Economy Mark cohort.

Portfolio

Eden's products are formulated using natural plant defence metabolites. They have been primarily used on high-value crops including vines, soft and stone fruit and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. The Company has three products currently on the market:

Mevalone® is a commercially available biofungicide that targets Botrytis, Sclerotinia, powdery and downy mildew. It is approved across multiple jurisdictions including the EU, US, Australia, New Zealand, Kenya and LATAM.

Cedroz™ is a commercially available bionematicide that targets nematodes in high-value crops. It is approved across the EU and US.

Ecovelex™ is a seed treatment undergoing the later stages of registration in the EU. It is a biological bird repellent used on maize seed. EU and UK regulatory submissions have been filed.

INO20 Insecticide is in development, and is expected to be launched in 2030. It targets spider mites, whitefly, aphids and thrips on a wide range of indoor and outdoor crops. Partner discussions are ongoing with news related to partnership formation expected in 2026.

Eden's Differentiator

Eden's products deliver multiple advantages over conventional products

- **Residue free** - Exempt from pesticide residue enabling use right up to harvest.
- **Polymer-free formulation** - Plastic-free encapsulation, aligned with global microplastics regulation.
- **High efficacy, solvent free and stable** - Efficacy often rivals or surpasses conventional leading products and typically outperforms competing biological products.
- **Crop safety** - The Sustaine® formulation technology delivers safe and effective plant protection.
- **Resistance management** - Plant-derived active ingredients offer a multi-site, membrane-disrupting action with no demonstrated tendency toward the emergence of pest resistance.
- **No pre-harvest intervals** - Low or no PHI gives growers flexibility, security and control.

Eden's products offer reliable, long-lasting control, are easy to apply, and provide greater stability and shelf life than other biological alternatives.

WALBROOK INVESTOR RELATIONS
For more information email: Eden@walbrookpr.com
Tel: 020 7933 8780; web: www.walbrookpr.com

Why Invest?

Eden is positioned to benefit from the growth of sustainable crop protection, supported by a portfolio of products, an IP portfolio and regulatory clearances across global markets. This is translating into growth, with revenues of £4.9m in the 15 months to March 2026. In April 2026, the company raised £10.8m, strengthening its cash position and providing resources to progress its pipeline of work. Product approvals have been granted in 33 countries, covering more than 100 crop uses, supporting further growth and expansion.

With its proprietary formulation technologies, asset-light partner model and near-term catalysts, including regulatory milestones and strategic partnerships, the Board believes Eden offers structural market growth, differentiated technology, regulatory and commercial validation, revenue growth and routes to value creation.

Strategic Partnerships

Eden has built strong relationships across the agricultural value chain with well-known industry leaders, combining its IP, formulation and regulatory expertise with the market access and capabilities of established industry partners including Corteva Agriscience, Syngenta, Sipcam Oxon and Eastman Chemical Company. Eden is well positioned to accelerate market adoption and unlock further partnership and licensing opportunities as demand for sustainable crop-protection solutions grows.

Market Opportunity

Eden operates in the global biological crop protection market, one of the fastest growing segments of agriculture. Demand is being driven by increasing restrictions on conventional chemical pesticides, growing consumer demand for residue-free food, the expansion of organic farming and the need for sustainable farming solutions. Eden estimates the global biopesticides market will exceed US$11 billion by 2027, growing at approximately 15% per annum, with the global seed treatment market projected to exceed US$12.5 billion.

The broader global pesticides market is valued at approximately US$91 billion in 2026 and is expected to grow to approximately US$143 billion over the next decade. Within this market, biopesticides and other bio-based crop protection solutions represent the fastest-growing segment, signalling significant opportunity for Eden.

The opportunity is supported by increasing regulatory pressure on conventional crop protection products, with more than 36 pesticides banned in the EU since July 2020. This creates a growing need for effective, sustainable biological alternatives and strengthens the long-term addressable market for Eden's products.

Key Newsflow

- **August 2026 -** Regulatory Approvals in Slovakia and Egypt
- **June 2026 -** Green Economy Mark
- **April 2026 -** Trading Update
- **February 2026 -** Thymolflex EPA Approval
- **January 2026 -** Novellus Regulatory Authorisation in Chile

Management Team

Sean Smith, Chief Executive Officer, joined Eden in 2014 and has more than 25 years' experience in the speciality chemicals and industrial biotechnology industries. He has held commercial leadership roles in blue-chip companies, including Ciba (now BASF) and Honeywell, and has spent much of his career in IP-based businesses. More recently, he has focussed on commercialising technology through licensing and new company formation.

Alex Abrey, Chief Financial Officer, joined the Board in 2007, having been Chief Accountant to Eden previously, and led the Company's admission on AIM in 2012. He has acted as Financial Director to a range of businesses, including a financial and management consultancy business, a medical waste management company and an intellectual property licensee. Alex is *a Chartered Certified Accountant.*

Meet Eden Research

Watch the Company's most recent investor presentation by clicking below

Forecasts (source: Factset)

	Dec'24 (Act.)	*Mar'26 (Act.)(15 months)**	*Mar'27 (Est.)*
Sales (£m)	*4.3*	*4.9*	*6.1*
Adj. EBITDA (£m)	*-1.6*	*-1.7*	*-0.9*

*Change in reporting date

For more information email: Eden@walbrookpr.com
Tel: 020 7933 8780; web: www.walbrookpr.com